Esperion Therapeutics has reached a settlement agreement with Alkem Laboratories Ltd. that extends market exclusivity for its cholesterol-reducing medications NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) through April 19, 2040. The agreement prevents Alkem from filing or marketing generic versions of the drugs in the United States during this period, marking the fifth such settlement Esperion has negotiated with abbreviated new drug application (ANDA) filers seeking to bring lower-cost alternatives to market.
This settlement follows similar agreements with other pharmaceutical manufacturers and reflects Esperion's ongoing efforts to protect its intellectual property portfolio surrounding these medications. The company has successfully resolved disputes with multiple generic drug makers, though patent litigation continues against four remaining defendants: Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, and Sandoz Inc.
The extended exclusivity period provides Esperion with substantial revenue protection for its key commercial products, which were developed to address cardiovascular risk reduction in patients with elevated cholesterol. The company's patent strategy demonstrates how branded pharmaceutical manufacturers negotiate settlements with generic competitors to maintain market exclusivity during patent disputes.